Rockville-based molecular diagnostics company, OpGen Inc.(Nasdaq: OPGN) has recently announced the sale of its commercial customer contracts and installed base of Unyvero systems to Singaporean family office, Camtech Pte Ltd.The deal, worth $218,000, comes as part of OpGen’s larger strategic move in light of the insolvency proceedings of its subsidiary, Curetis.
OpGen specializes in providing molecular diagnostic solutions and informatics services to address global healthcare challenges, particularly in the field of infectious diseases.Their innovative technologies empower healthcare professionals in effective identification, treatment, and prevention of infectious pathogens.The company currently has 8.778152 million shares outstanding, with a current price of $0.409.
OpGen’s decision to sell its commercial customer contracts and Unyvero system installations signifies a strategically necessary shift in its business model.The sale follows Camtech’s prior acquisition of Curetis and its assets, rights, and businesses.With OpGen’s entry into this agreement, the company can streamline its operations and focus on core areas of expertise, seeking new opportunities for growth and development.
The sale of Unyvero systems is a pivotal move for OpGen, freeing up resources and capital that can be redirected towards other strategic objectives.While Unyvero systems have played a significant role in OpGen’s business, the company’s decision to divest from this particular segment allows them to concentrate on their core competencies.
By offloading commercial customer contracts and installed base of Unyvero systems to Camtech, OpGen signals its intent to adapt to prevailing market dynamics and capitalize on new strategic opportunities.While the financial figures of the deal may appear modest, the long-term impact of this strategic shift could be substantial for OpGen.
Moving forward, OpGen will need to leverage its molecular diagnostic solutions and informatics services to remain competitive in the ever-evolving landscape of combating infectious diseases.The company’s ability to develop and deploy innovative technologies plays a critical role in supporting healthcare professionals as they combat the spread of infectious pathogens globally.
OpGen’s sale of Unyvero systems to Camtech not only helps the company streamline its operations but also positions it to explore newer avenues for growth and innovation.As OpGen continues to provide updates on its business operations and strategic opportunities, stakeholders and investors eagerly await news on how the company plans to capitalize on its strengthened position in the molecular diagnostics industry.
Comments